A patient walks into your independent pharmacy wearing sunglasses and a wide-brimmed hat. She places Excedrin PM and Excedrin Migraine on the counter She whispers: "that is all." Which of the following is true if the patient plans to take these two medications together?

A. The patient should not take both of these together because it is a therapeutic duplication: Both Excedrin PM and Excedrin Migraine contain acetaminophen and sometimes other overlapping ingredients such as caffeine or diphenhydramine. Taking them together increases the risk of exceeding safe acetaminophen limits, leading to hepatotoxicity, and may result in excessive sedation from diphenhydramine. B. The patient should not take both of these together, they cancel each other out: There is no evidence that these medications negate each other’s effects. Both are intended for pain relief, and taking them together does not reduce their efficacy, it increases risk of toxicity. C. The patient can take both of these together, but there is a theoretical drug interaction: While drug interactions are a consideration, the primary issue here is overlapping active ingredients, which constitutes direct therapeutic duplication rather than a theoretical interaction. D. The patient can take both of these together if she doubles the dose of Excedrin PM: Doubling the dose would dangerously increase acetaminophen and diphenhydramine intake, raising the risk of liver injury, sedation, and other adverse effects. This is unsafe and not recommended.